Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carya cordiformis pollen extract
- Development stage
- Unknown
- Lead developer
- Jubilant
- Administration
- Dermal, Intradermal
01
Overview
Carya cordiformis pollen extract is a biological diagnostic agent derived from the pollen of the bitternut hickory tree. It is used in clinical settings for the diagnosis of pollen-induced allergic rhinitis, allergic conjunctivitis, and asthma through skin prick or intradermal testing. Upon administration, the allergens in the extract cross-link specific IgE antibodies bound to the surface of mast cells and basophils in sensitized patients, resulting in the release of histamine and other mediators that produce a visible wheal-and-flare reaction. It is primarily used as an in vivo diagnostic tool rather than a therapeutic agent.
- Other names
- Bitternut hickory pollen extractCarya cordiformis pollen
02
Targets
IgE (Immunoglobulin E)
Beyond the preview
Go deeper on carya cordiformis pollen extract.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carya cordiformis pollen extract.